Close Menu

head and neck cancer

The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.

The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.

Clinicians can use the PD-L1 IHC 22C3 pharmDx assay to help identify head and neck squamous cell carcinoma patients for treatment with Merck's Keytruda in Europe.

Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.

The diagnostic can now be used to identify patients with head and neck squamous cell carcinoma who may benefit from first-line treatment with Keytruda.

Using a technology called optical stretching, investigators found that they could distinguish oral cancer cells from normal cells based on how soft or deformable they were.

The five-year award will go toward developing a tool that will be based on digitized hematoxylin and eosin (H&E)-stained pathology images alone.

The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.

The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.

New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.